Meeting
2020 ASCO Virtual Scientific Program
Value of multigene panel retesting of families with BRCA1/2 mutation-negative hereditary breast and ovarian cancer (HBOC).
Authors
Ekaterina Meshoulam Nikolaeva
Mutua Terrassa, Terrassa, Spain
Ekaterina Meshoulam Nikolaeva , Raul Terés , Daniela Camacho , Aida Bujosa , Maria Borrell , Pablo Gallardo , Berta Martin , Nuria Calvo , Consol Lopez , Rosa Alfonso , Carla Sola , Monia Cornet , Nuria Cliville , Adriana Lasa , Ariadna Tibau , Cristina Arqueros , Agusti Barnadas , Teresa Ramon y Cajal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1582)
DOI
10.1200/JCO.2020.38.15_suppl.1582
Abstract #
1582
Poster Bd #
74
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families.
First Author: Jan Hauke
Poster
2017 ASCO Annual Meeting
Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.
First Author: Gregory Idos
Poster
2019 ASCO Annual Meeting
Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative.
First Author: Allison W. Kurian
Poster
2017 ASCO Annual Meeting
Expanded yield of multiplex panel testing in fully accrued prospective trial.
First Author: Gregory Idos